Treatment with macrolides and glucocorticosteroids in severe communityacquired pneumonia: A post-hoc exploratory analysis of a randomized controlled trial

PLoS ONE

Volumn 12, Issue 6, 2017, Pages

  Ceccato, Adrian ^a,b   Cilloniz, Catia ^a   Ranzani, Otavio T ^a,c   Menendez, Rosario ^d   Agusti, Carles ^a   Gabarrus, Albert ^a   Ferrer, Miquel ^a   Sibila, Oriol ^e   Niederman, Michael S ^f   Torres, Antoni ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b HOSPITAL NACIONAL PROFESOR ALEJANDRO POSADAS   (Argentina)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA LACTAM ANTIBIOTIC; C REACTIVE PROTEIN; MACROLIDE; METHYLPREDNISOLONE; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; GLUCOCORTICOID;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; COMBINATION DRUG THERAPY; COMMUNITY ACQUIRED PNEUMONIA; COMORBIDITY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DRUG TREATMENT FAILURE; EXPLORATORY RESEARCH; FEMALE; HOSPITAL ADMISSION; HOSPITAL MORTALITY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); CLINICAL TRIAL; COMMUNITY-ACQUIRED INFECTIONS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; MULTICENTER STUDY; PNEUMONIA, BACTERIAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MACROLIDES; MALE; METHYLPREDNISOLONE; MIDDLE AGED; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 85020822785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0178022     Document Type: Article

References (36)

1. Fine MJ, Smith MA, Carson CA, Mutha SS, Sankey SS, Weissfeld LA, et al. Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis. JAMA. 1996; 275: 134-141. PMID: 8531309
2. Restrepo MI, Mortensen EM, Velez JA, Frei C, Anzueto A. A comparative study of community-acquired pneumonia patients admitted to the ward and the ICU. Chest. 2008; 133: 610-617. https://doi.org/10. 1378/chest.07-1456 PMID: 17989157
3. Ramírez P, Ferrer M, Martí V, Reyes S, Martínez R, Menéndez R, et al. Inflammatory biomarkers and prediction for intensive care unit admission in severe community-acquired pneumonia. Crit Care Med. 2011; 39: 2211-2217. https://doi.org/10.1097/CCM.0b013e3182257445 PMID: 21705887
4. Menéndez R, Martínez R, Reyes S, Mensa J, Filella X, Marcos MA, et al. Biomarkers improve mortality prediction by prognostic scales in community-acquired pneumonia. Thorax. 2009; 64: 587-591. https:// doi.org/10.1136/thx.2008.105312 PMID: 19131448
5. van Werkhoven CH, Huijts SM, Bolkenbaas M, Grobbee DE, Bonten MJM. The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015; 61: 1835-1838. https://doi.org/10.1093/cid/civ686 PMID: 26265498
6. Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. Semin Immunol. 2012; 24: 331-341. https://doi.org/10.1016/j.smim.2012.04.008 PMID: 22560929
7. Gudiol C, Royo-Cebrecos C, Laporte J, Ardanuy C, Garcia-Vidal C, Antonio M, et al. Clinical features, aetiology and outcome of bacteraemic pneumonia in neutropenic cancer patients. Respirol Carlton Vic. 2016; 21: 1411-1418. https://doi.org/10.1111/resp.12848 PMID: 27417156
8. Annane D, Timsit J-F, Megarbane B, Martin C, Misset B, Mourvillier B, et al. Recombinant human activated protein C for adults with septic shock: a randomized controlled trial. Am J Respir Crit Care Med. 2013; 187: 1091-1097. https://doi.org/10.1164/rccm.201211-2020OC PMID: 23525934
9. Alejandria MM, Lansang MAD, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev. 2013; CD001090. https://doi.org/10. 1002/14651858.CD001090.pub2 PMID: 24043371
10. Asadi L, Sligl WI, Eurich DT, Colmers IN, Tjosvold L, Marrie TJ, et al. Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and metaanalysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2012; 55: 371-380. https://doi.org/10.1093/cid/ cis414 PMID: 22511553
11. Mortensen EM, Halm EA, Pugh MJ, Copeland LA, Metersky M, Fine MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia. JAMA. 2014; 311: 2199-2208. https://doi.org/10.1001/jama.2014.4304 PMID: 24893087
12. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA. 2015; 313: 677-686. https://doi.org/10.1001/jama. 2015.88 PMID: 25688779
13. Blum CA, Nigro N, Briel M, Schuetz P, Ullmer E, Suter-Widmer I, et al. Adjunct prednisone therapy for patients with community-acquired pneumonia: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Lond Engl. 2015; 385: 1511-1518. https://doi.org/10.1016/S0140-6736(14)62447-8
14. Wan Y-D, Sun T-W, Liu Z-Q, Zhang S-G, Wang L-X, Kan Q-C. Efficacy and Safety of Corticosteroids for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. Chest. 2016; 149: 209-219. https://doi.org/10.1378/chest.15-1733 PMID: 26501852
15. Sibila O, Luna CM, Agustí C, Baquero S, Gando S, Patrón JR, et al. Effects of glucocorticoids in ventilated piglets with severe pneumonia. Eur Respir J. 2008; 32: 1037-1046. https://doi.org/10.1183/ 09031936.00009208 PMID: 18508831
16. Siemieniuk RAC, Meade MO, Alonso-Coello P, Briel M, Evaniew N, Prasad M, et al. Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med. 2015; 163: 519-528. https://doi.org/10.7326/M15-0715 PMID: 26258555
17. Altenburg J, de Graaff CS, van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics - part 1: biological mechanisms. Respir Int Rev Thorac Dis. 2011; 81: 67-74. https://doi.org/ 10.1159/000320319 PMID: 20733281
18. Arfè A, Blasi F, Merlino L, Corrao G. Respiratory drugs and macrolides prevent asthma exacerbations: A real-world investigation. Respir Med. 2016; 119: 7-12. https://doi.org/10.1016/j.rmed.2016.05.004 PMID: 27692150
19. Albert RK, Connett J, Bailey WC, Casaburi R, Cooper JAD, Criner GJ, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698. https://doi.org/10.1056/ NEJMoa1104623 PMID: 21864166
20. Saiman L, Marshall BC, Mayer-Hamblett N, Burns JL, Quittner AL, Cibene DA, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290: 1749-1756. https://doi.org/10.1001/jama.290.13.1749 PMID: 14519709
21. Rogers GB, Bruce KD, Martin ML, Burr LD, Serisier DJ. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled BLESS trial. Lancet Respir Med. 2014; 2: 988-996. https://doi. org/10.1016/S2213-2600(14)70213-9 PMID: 25458200
22. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis Off Publ Infect Dis Soc Am. 2007; 44 Suppl 2: S27-72. https://doi.org/10.1086/511159 PMID: 17278083
23. Fine MJ, Auble TE, Yealy DM, Hanusa BH, Weissfeld LA, Singer DE, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997; 336: 243-250. https://doi. org/10.1056/NEJM199701233360402 PMID: 8995086
24. Ewig S, Ruiz M, Mensa J, Marcos MA, Martinez JA, Arancibia F, et al. Severe community-acquired pneumonia. Assessment of severity criteria. Am J Respir Crit Care Med. 1998; 158: 1102-1108. https:// doi.org/10.1164/ajrccm.158.4.9803114 PMID: 9769267
25. Halm EA, Fine MJ, Marrie TJ, Coley CM, Kapoor WN, Obrosky DS, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia: implications for practice guidelines. JAMA. 1998; 279: 1452-1457. PMID: 9600479
26. Martínez R, Menéndez R, Reyes S, Polverino E, Cillóniz C, Martínez A, et al. Factors associated with inflammatory cytokine patterns in community-acquired pneumonia. Eur Respir J. 2011; 37: 393-399. https://doi.org/10.1183/09031936.00040710 PMID: 20595152
27. Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008; 31: 12-20. https://doi.org/10.1016/j.ijantimicag.2007.08. 001 PMID: 17935949
28. Tagliabue C, Salvatore CM, Techasaensiri C, Mejias A, Torres JP, Katz K, et al. The impact of steroids given with macrolide therapy on experimental Mycoplasma pneumoniae respiratory infection. J Infect Dis. 2008; 198: 1180-1188. https://doi.org/10.1086/591915 PMID: 18717637
29. Sun X-J, Li Z-H, Zhang Y, Zhou G, Zhang J-Q, Deng J-M, et al. Combination of erythromycin and dexamethasone improves corticosteroid sensitivity induced by CSE through inhibiting PI3K-δ/Akt pathway and increasing GR expression. Am J Physiol Lung Cell Mol Physiol. 2015; 309: L139-146. https://doi. org/10.1152/ajplung.00292.2014 PMID: 25957293
30. Lorenzo M-J, Moret I, Sarria B, Cases E, Cortijo J, Méndez R, et al. Lung inflammatory pattern and antibiotic treatment in pneumonia. Respir Res. 2015; 16: 15. https://doi.org/10.1186/s12931-015-0165-y PMID: 25849726
31. Wirz SA, Blum CA, Schuetz P, Albrich WC, Noppen C, Mueller B, et al. Pathogen-and antibiotic-specific effects of prednisone in community-acquired pneumonia. Eur Respir J. 2016; 48: 1150-1159. https:// doi.org/10.1183/13993003.00474-2016 PMID: 27471201
32. Kovaleva A, Remmelts HHF, Rijkers GT, Hoepelman AIM, Biesma DH, Oosterheert JJ. Immunomodulatory effects of macrolides during community-acquired pneumonia: a literature review. J Antimicrob Chemother. 2012; 67: 530-540. https://doi.org/10.1093/jac/dkr520 PMID: 22190609
33. Dalhoff A. Immunomodulatory activities of fluoroquinolones. Infection. 2005; 33 Suppl 2: 55-70. https:// doi.org/10.1007/s15010-005-8209-8 PMID: 16518713
34. Dalhoff A, Shalit I. Immunomodulatory effects of quinolones. Lancet Infect Dis. 2003; 3: 359-371. PMID: 12781508
35. Menéndez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008; 63: 447-452. https://doi.org/10. 1136/thx.2007.086785 PMID: 18245147
36. Menéndez R, Torres A, Zalacaín R, Aspa J, Martín Villasclaras JJ, Borderías L, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004; 59: 960-965. https://doi.org/10.1136/thx.2003.017756 PMID: 15516472